Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03438708 · ClinicalTrials.gov registry record · Phase 2
Prior Axitinib as a Determinant of Outcome of Renal Surgery
A Phase 2 study of Clear Cell Renal Cell Carcinoma, sponsored by University of California, San Diego.
- Active
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 2
- Study locations
NCT03438708 is a Phase 2 study of Clear Cell Renal Cell Carcinoma that is active but no longer recruiting, run by University of California, San Diego. The registered enrollment target is 22 participants, below the 203-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03438708, a Phase 2 study of Clear Cell Renal Cell Carcinoma, is active but no longer recruiting, sponsored by University of California, San Diego.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a single arm phase II study of axitinib in patients with clear cell renal cell carcinoma (RCC) with strong indications for partial nephrectomy (PN) for whom PN is not currently possible due to anatomic considerations and residual renal function concerns. Evaluation of tumor downsizing will be performed including changes of tumor complexity by nephrometry score. A total of 50 participants will be enrolled. It is hypothesized that pretreatment with axitinib will be safe and improve the feasibility of complex nephron sparing surgery in select patients with localized clear cell RCC and imperative indications for partial nephrectomy.
Conditions Studied
Interventions
- DRUG Axitinib Oral Tablet [Inlyta]
Study Locations (2)
California
- UC San Diego Moores Cancer Center - La Jolla
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2018-03-05 |
| Est. Completion | 2026-03-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03438708
The ClinicalTrials.gov registry entry for NCT03438708 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 203-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (89% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Axitinib Oral Tablet [Inlyta] is the first listed.
NCT03438708 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Ohio.
Frequently Asked Questions
What is clinical trial NCT03438708 about?
NCT03438708 is a clinical study titled "Prior Axitinib as a Determinant of Outcome of Renal Surgery". This is a single arm phase II study of axitinib in patients with clear cell renal cell carcinoma (RCC) with strong indications for partial nephrectomy (PN) for whom PN is not currently possible due to anatomic considerations and residual renal function concerns. Evaluation of tumor downsizing will b...
What is the current status of trial NCT03438708?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2018-03-05. Estimated completion is 2026-03-04.
What conditions does trial NCT03438708 study?
This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma.
What interventions are being tested in trial NCT03438708?
The interventions under investigation include: Axitinib Oral Tablet [Inlyta] (DRUG).
Who is sponsoring clinical trial NCT03438708?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03438708 being conducted?
This trial has 2 study locations across California, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clear Cell Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
RECRUITING · Phase 2
-
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
RECRUITING · Phase 2
-
Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
RECRUITING · Phase 2
-
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.